+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Krystal Biotech Inc (KRYS) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 49 Pages
  • April 2025
  • GlobalData
  • ID: 5960489
Krystal Biotech Inc (KRYS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Krystal Biotech Inc (Krystal Biotech) is a gene therapy company that carries out the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs, especially dermatological diseases. The company’s only marketed product is VYJUVEK/B-VEC (bercolagene telserpavec), which is a gene therapy for the treatment of dystrophic epidermolysis bullosa (DEB). Krystal Biotech uses its patented gene therapy technology platform based on engineered HSV-1 to create vectors that deliver therapeutic transgenes to cells of interest in multiple organ systems. The company’s pipeline products include KB105, KB407, KB104, KB408, and KB707. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania, the US.

Krystal Biotech Inc Key Recent Developments

  • Apr 24, 2025: Krystal Biotech To Present at Upcoming Scientific Conferences
  • Apr 17, 2025: Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025
  • Apr 07, 2025: Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer
  • Feb 19, 2025: Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Krystal Biotech Inc - Key Facts
  • Krystal Biotech Inc - Key Employees
  • Krystal Biotech Inc - Key Employee Biographies
  • Krystal Biotech Inc - Major Products and Services
  • Krystal Biotech Inc - History
  • Krystal Biotech Inc - Company Statement
  • Krystal Biotech Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Krystal Biotech Inc - Business Description
  • R&D Overview
  • Krystal Biotech Inc - Corporate Strategy
  • Krystal Biotech Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Krystal Biotech Inc - Strengths
  • Krystal Biotech Inc - Weaknesses
  • Krystal Biotech Inc - Opportunities
  • Krystal Biotech Inc - Threats
  • Krystal Biotech Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Krystal Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
  • Krystal Biotech Inc, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
  • Krystal Biotech Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Apr 24, 2025: Krystal Biotech To Present at Upcoming Scientific Conferences
  • Apr 17, 2025: Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025
  • Apr 07, 2025: Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer
  • Feb 19, 2025: Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results
  • Jan 14, 2025: Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer
  • Aug 28, 2024: Jeune Aesthetics Announces Phase 1 Positive Interim Safety And Efficacy Results For KB301 In The Treatment Of Lateral Canthal Lines And Wrinkles
  • May 08, 2024: Krystal Biotech to Present at BofA Securities 2024 Health Care Conference
  • Feb 26, 2024: Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Krystal Biotech Inc, Key Facts
  • Krystal Biotech Inc, Key Employees
  • Krystal Biotech Inc, Key Employee Biographies
  • Krystal Biotech Inc, Major Products and Services
  • Krystal Biotech Inc, History
  • Krystal Biotech Inc, Subsidiaries
  • Krystal Biotech Inc, Key Competitors
  • Krystal Biotech Inc, Ratios based on current share price
  • Krystal Biotech Inc, Annual Ratios
  • Krystal Biotech Inc, Interim Ratios
  • Krystal Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
  • Krystal Biotech Inc, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
  • Krystal Biotech Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Krystal Biotech Inc, Performance Chart (2020 - 2024)
  • Krystal Biotech Inc, Ratio Charts
  • Krystal Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
  • Krystal Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Wave Life Sciences Ltd
  • Revance Therapeutics Inc
  • Pfizer Inc
  • Galderma SA
  • Eliksa Therapeutics Inc
  • AbbVie Inc
  • Peak Biosciences Inc
  • Merck & Co Inc
  • Adaptive Biotechnologies Corp
  • Abeona Therapeutics Inc
  • Sanofi
  • Recode Therapeutics Inc
  • Johnson & Johnson
  • Grifols SA
  • Bristol-Myers Squibb Co
  • Leo Pharma AS
  • Chiesi Farmaceutici SpA
  • Castle Creek Biosciences Inc
  • RHEACELL GmbH & Co KG
  • Phoenix Tissue Repair Inc
  • Novo Nordisk AS
  • 4D Molecular Therapeutics Inc
  • Vertex Pharmaceuticals Inc
  • Takeda Pharmaceutical Co Ltd
  • Intellia Therapeutics Inc
  • Merz Pharmaceuticals GmbH
  • Patagonia Pharmaceuticals LLC
  • Mereo Biopharma Group Plc